JP2024537323A5 - - Google Patents

Info

Publication number
JP2024537323A5
JP2024537323A5 JP2024522070A JP2024522070A JP2024537323A5 JP 2024537323 A5 JP2024537323 A5 JP 2024537323A5 JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024537323 A5 JP2024537323 A5 JP 2024537323A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/125725 external-priority patent/WO2023061505A1/en
Publication of JP2024537323A publication Critical patent/JP2024537323A/ja
Priority to JP2025006663A priority Critical patent/JP2025061426A/ja
Publication of JP2024537323A5 publication Critical patent/JP2024537323A5/ja
Pending legal-status Critical Current

Links

JP2024522070A 2021-10-15 2022-10-17 抗グリピカン３抗体 Pending JP2024537323A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006663A JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/124182 2021-10-15
CN2021124182 2021-10-15
PCT/CN2022/125725 WO2023061505A1 (en) 2021-10-15 2022-10-17 Anti-glypican 3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006663A Division JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Publications (2)

Publication Number Publication Date
JP2024537323A JP2024537323A (ja) 2024-10-10
JP2024537323A5 true JP2024537323A5 (https=) 2025-11-10

Family

ID=85988149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024522070A Pending JP2024537323A (ja) 2021-10-15 2022-10-17 抗グリピカン３抗体
JP2025006663A Pending JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006663A Pending JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Country Status (5)

Country Link
US (2) US20240409663A1 (https=)
EP (2) EP4416187A1 (https=)
JP (2) JP2024537323A (https=)
CN (3) CN118488970A (https=)
WO (1) WO2023061505A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4591887A1 (en) * 2022-09-22 2025-07-30 Lepu Biopharma Co., Ltd. Gpc3 antibody-drug conjugate and use thereof
WO2024067764A1 (zh) * 2022-09-30 2024-04-04 信立泰(成都)生物技术有限公司 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途
WO2025045242A1 (zh) * 2023-09-01 2025-03-06 信立泰(成都)生物技术有限公司 一种靶向gpc3的双特异性抗体或抗原结合片段及其用途
TW202525864A (zh) * 2023-09-05 2025-07-01 大陸商上海美雅珂生物技術有限責任公司 靶向ｇｐｃ３的抗體藥物偶聯物及其應用
WO2025159562A1 (ko) * 2024-01-24 2025-07-31 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도
WO2026016998A1 (zh) * 2024-07-15 2026-01-22 北京剂泰医药科技有限公司 编码针对GPC3和CD3双特异性抗体的mRNA分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
ME02345B (me) * 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
CN101633693A (zh) * 2009-08-24 2010-01-27 中国人民解放军第二军医大学 一种抗gpc3的单克隆抗体
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
US9926377B2 (en) * 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
ES2883240T3 (es) * 2015-08-03 2021-12-07 Cafa Therapeutics Ltd Anticuerpo contra glipicano-3 y aplicación del mismo
US11767362B1 (en) * 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
CN109021108B (zh) * 2018-08-27 2019-06-25 南京医科大学 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用
KR20220083665A (ko) * 2019-08-01 2022-06-20 알.피.쉐러 테크놀러지즈 엘엘씨 Gpc3에 특이적인 항체 및 그것의 사용 방법

Similar Documents

Publication Publication Date Title
JP2024537323A5 (https=)
JP2023511774A5 (https=)
JP2024150445A5 (https=)
JP2022513420A5 (https=)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2022553922A5 (https=)
JP2011501656A5 (https=)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
RU2020103344A (ru) Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
JP2023549537A5 (https=)
CA2487060A1 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
RU2020113027A (ru) Axl-специфичные антитела и их применения
JP2025069432A5 (https=)
JP2024001073A5 (https=)
JP2021512107A5 (https=)
JP2022545741A5 (https=)
JP2020534012A5 (https=)
JP2023543826A5 (https=)
JP2023544143A5 (https=)
JP2024540148A5 (https=)
JP2022512646A5 (https=)
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
JP2018528759A5 (https=)
JP2022500382A5 (https=)